{
    "clinical_study": {
        "@rank": "28539", 
        "acronym": "RELIEF", 
        "arm_group": [
            {
                "arm_group_label": "Rebif\u00ae Morning Administration", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Rebif\u00ae Evening  Administration", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase\n      4 study to assess whether the morning administration of interferon beta 1a (Rebif\u00ae) leads to\n      a lower severity of flu-like symptoms (FLS) as compared to the evening administration, in\n      subjects with relapsing multiple sclerosis (RMS)."
        }, 
        "brief_title": "A Study of Rebif\u00ae in Subjects With Relapsing Multiple Sclerosis", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis, Relapsing-Remitting", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females between 18 and 60 years of age\n\n          -  Female subjects must be neither pregnant nor breast-feeding and must lack\n             child-bearing potential. Furthermore, female subjects must not have been pregnant\n             from at least three months prior to enter in the study\n\n          -  Subjects have RMS according to the revised McDonald Criteria (2010)\n\n          -  Subjects with an expanded disability status scale (EDSS) score of less than 6.0\n\n          -  Subjects naive to treatment and eligible for treatment with Rebif\u00ae 44 three times a\n             week, or patients having received glatiramer acetate with a wash-out from at least\n             one month, or patients having received treatment with natalizumab or fingolimod with\n             a wash-out from at least three months\n\n          -  Subjects able to self-inject treatment using RebiSmart\u00ae\n\n          -  Subjects willing and able to comply with the protocol for the duration of the study\n\n          -  Subjects have given written informed consent to take part in the study\n\n        Exclusion Criteria:\n\n          -  Subjects have any disease other than MS that could better explain his/her signs and\n             symptoms\n\n          -  Subjects who have received any immunosuppressive agents within 3 months prior to\n             Baseline\n\n          -  Subjects who have received any corticosteroids within 30 days prior to Baseline\n\n          -  Subjects have a MS relapse within 30 days prior to Baseline\n\n          -  Subjects have inadequate liver function and bone marrow reserve as defined in the\n             protocol\n\n          -  Subjects have moderate to severe renal impairment\n\n          -  Subjects have any visual or physical impairment that precludes the subjects from\n             self-injecting the treatment using RebiSmart\u00ae\n\n          -  Subjects have hypersensitivity to natural or recombinant interferon, or to any of its\n             excipients\n\n          -  Subjects have any contra-indications to treatment with interferon (IFN) beta 1a\n             according to Summary of Product Characteristics (SmPC)\n\n          -  Subjects have any contra-indications to treatment with ibuprofen/paracetamol\n             according to SmPC\n\n          -  Obese subjects, defined by body mass index greater than 30 kilogram per square meter\n             (kg/m^2)\n\n          -  Subjects have participated in any other investigational trial within 30 days from\n             Baseline\n\n          -  Subjects have any other significant disease that in the Investigator's opinion would\n             exclude the subject from the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "218", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064816", 
            "org_study_id": "200136-570", 
            "secondary_id": "2013-004450-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rebif\u00ae Morning Administration", 
                "description": "Rebif\u00ae will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart\u00ae self-injector device for 12 weeks.", 
                "intervention_name": "Rebif\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rebif\u00ae Evening  Administration", 
                "description": "Rebif\u00ae will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart\u00ae self-injector device for 12 weeks.", 
                "intervention_name": "Rebif\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interferon beta 1a"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple Sclerosis, Relapsing-Remitting", 
            "Interferon beta 1a", 
            "Rebif\u00ae"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49 6151 72 5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif\u00ae) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck Serono S.P.A., Italy", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: Ethics Committee", 
                "Italy: National Institute of Health", 
                "Italy: The Italian Medicines Agency"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Flu-like Symptoms (FLS) score at Week 12", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064816"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Flu-like Symptoms (FLS) score at Weeks 4 and 8", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4 and 8"
            }, 
            {
                "description": "MSTCQ score of Injection Site Reaction (ISR) subscale, Global Side-Effects subscale, Benefits, Short-Form McGill Pain Questionnaire, Visual Analogue Scale (VAS), and pain rating subscale at Weeks 4, 8 and 12 will be reported.", 
                "measure": "Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale scores at Weeks 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Change from Baseline in Hospital Anxiety and Depression Scale (HADS) subscale and total score at Weeks 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Change from Baseline in Fatigue Severity Scale (FSS) score at Weeks 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) score at Weeks 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Change from Baseline in Multiple Sclerosis International Quality of Life (MusiQoL) score at Weeks 4, 8 and 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Percentage of subjects with adherence to treatment", 
                "safety_issue": "No", 
                "time_frame": "Weeks 4, 8 and 12"
            }, 
            {
                "measure": "Change from Baseline in circulating levels of cytokines at Week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }, 
            {
                "measure": "Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Week 12 or early study termination"
            }, 
            {
                "measure": "Correlation between change from Baseline in circulating levels of cytokines at Week 12 and FLS score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 12"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}